INTRODUCTION
============

One of the most important determinants influencing the outcomes of patients in the intensive care unit (ICU), especially those with serious infectious diseases (IDs), is antibiotic resistance. This influence is due largely to the tendency for prevalence of endemic antibiotic resistance in ICU patient populations because of the extensive use of empirical broad-spectrum antimicrobial agents in the ICU, the weakened immune systems of patients, and the frequent use of invasive devices (e.g., venous cannulae) that impact anatomical integrity and protective barriers \[[@b1-kjim-2018-169]-[@b3-kjim-2018-169]\]. These high rates of antibiotic resistance in the ICU, which are growing, are associated with high morbidity and mortality rates and costly hospitalization stays \[[@b4-kjim-2018-169],[@b5-kjim-2018-169]\]. Therefore, to improve patient outcomes and lower healthcare costs, a major objective of many hospitals is to reduce the prevalence of multidrug-resistant (MDR) bacterial infections, especially in the ICU \[[@b4-kjim-2018-169],[@b6-kjim-2018-169]\]. One approach to do so is to reduce the duration of empirical broad-spectrum antibiotic therapy by using novel diagnostic tools that are now widely available. These tools can rapidly identify the microorganisms with which patients are infected, thereby promoting the more judicious use of antibiotics \[[@b7-kjim-2018-169]-[@b10-kjim-2018-169]\].

One of these new tools used for rapid pathogen identification is matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS). It is increasingly being used in hospitals worldwide to identify microorganisms, and several recent studies have shown that it improves the clinical outcomes of patients, especially those with bacteremia \[[@b11-kjim-2018-169]-[@b14-kjim-2018-169]\]. However, in Korea, critical care delivery systems are underdeveloped compared with those in Western countries \[[@b15-kjim-2018-169]-[@b17-kjim-2018-169]\]. As a result, newly developed rapid pathogen identification tools such as MALDI-TOF MS have not been fully introduced into clinical practice. Therefore, whether MALDI-TOF MS can also be useful for Korean patients with MDR bacteremia remains unclear.

To address this issue, the present study evaluated the clinical efficacy of rapid microorganism identification using MALDI-TOF MS in Korean patients with MDR bacteremia in the ICU by comparing two patient groups: one from before the introduction and one from after the introduction of MALDI-TOF MS in our institution.

METHODS
=======

Study design, ethics, and subject selection
-------------------------------------------

This retrospective quasi-experimental pre--post-intervention study included all consecutive patients who had positive blood culture tests in the ICUs of Pusan National University Hospital, Busan, Korea, between March 2011 and February 2013 and between March 2014 and February 2016. MALDI-TOF MS was introduced in the hospital between these two study periods (i.e., between March 2013 and February 2014). Thus, the patients were divided into the pre-intervention group, in which microorganisms were identified by conventional methods between March 2011 and February 2013, and the intervention group, in which microorganisms were identified by MALDI-TOF MS between March 2014 and February 2016 (all patients in the intervention group underwent microorganism indentification using MALDI-TOF MS only). This study was approved by the Institutional Review Board of Pusan National University Hospital (C-1703-004-052). The need for informed consent from patients was waived due to the observational and retrospective nature of this study. Our study had no impact on the treatment of the patients included.

Pusan National University Hospital is a university-affiliated tertiary referral academic care hospital with 1,100 beds. It has six functionally separate ICUs with 85 beds (medical, 12 beds; surgical, 10 beds; cardio-stroke, 14 beds; neurosurgical, 13 beds; emergency, 20 beds; and trauma, 16 beds). All ICUs have full cardiovascular and close airway monitoring equipment. Each has one full-time ICU specialist. All patients were managed according to therapeutic recommendations based on sepsis survival guidelines and a lung-protective ventilator strategy \[[@b18-kjim-2018-169],[@b19-kjim-2018-169]\].

Patients in the ICU were included in the study if they were ≥ 18 years of age, had positive blood culture tests during their ICU care, and were shown by conventional methods or MALDI-TOF MS to have one of the following six MDR bacteria: methicillin-resistant *Staphylococcus aureus* (MRSA), extended-spectrum β-lactamase (ESBL)-producing Gram-negative bacteria (*Escherichia coli* and *Klebsiella pneumoniae*), carbapenem-resistant Gram-negative rods (*Acinetobacter baumannii* \[CRAB\] and *Pseudomonas aeruginosa* \[CRPA\]), and vancomycin-resistant *Enterococcus faecium* (VRE). Patients with polymicrobial bacteremia or a subsequent bacteremia episode after the first (index) bacteremia event were excluded in accordance with the study design of Lockwood et al. \[[@b13-kjim-2018-169]\].

All investigators contributed to the design of the study and confirmed that the study objectives and procedures were honestly disclosed. Between September 2016 and February 2017, the electronic medical records of all enrolled patients were reviewed retrospectively. The relevant medical, laboratory, and radiological data were extracted and used to complete a case report form for each patient, and the data were analyzed.

Microbiology workflow
---------------------

Blood samples were sent to the microbiology laboratory and were used to inoculate plates containing the appropriate solid agar media as soon as they were received. At the same time, all specimens were Gram stained. Positive blood cultures from the pre-intervention group underwent microorganism identification using conventional and automated biochemical methods (VITEK-2, bioMérieux, Marcy l'Etoile, France). Positive blood cultures from the intervention group underwent microorganism identification using MALDI-TOF MS (Bruker Daltonics, Bremen, Germany). In both groups, antimicrobial susceptibility testing was performed using the VITEK-2 and E-test methods (bioMérieux). The laboratory identified microorganisms and performed antimicrobial susceptibility testing once a day at 9:00 AM for both groups.

Data collection
---------------

The following demographic and clinical data were gathered from the medical records of each patient: age, sex, comorbidities before ICU admission, and lengths of ICU stay, hospital stay, and ventilator care. The severity of illness was measured using Acute Physiology and Chronic Health Evaluation (APACHE) II scoring, and accompanying organ failure was measured using Sequential Organ Failure Assessment (SOFA) scoring \[[@b20-kjim-2018-169],[@b21-kjim-2018-169]\]. The APACHE II and SOFA scores were calculated based on laboratory and clinical data recorded on the day of venipuncture for blood culture.

Microbiological information, including microorganism identification and antimicrobial susceptibility test results, were also extracted from the medical records. The time from venipuncture to microorganism identification and antibiotic susceptibility testing was noted. A subset of patients underwent antibiotic adjustment based on the antibiotic susceptibility test results. In these cases, we also determined the time from venipuncture to antibiotic adjustment. Whether an ID specialist was consulted was also evaluated. The antibiotics used for more than 3 days in the 3 months before blood was drawn in the ICU for microorganism culture were also recorded for all patients.

The primary source of infection at the time of ICU admission was also recorded. Moreover, whether the patient needed hemodialysis (defined as use of any form of renal replacement therapy), neuromuscular blocking agents, vasopressors, and/or ventilator care on the day of venipuncture for microorganism culture was documented. Survivors were defined as patients who survived for 28 days after blood was drawn.

Statistical analysis
--------------------

Continuous variables are expressed as mean ± standard deviation and categorical variable are expressed as number (%). Continuous variables in the pre-intervention and intervention groups were compared using Student t test, and categorical variables were compared using the chi-square test or Fisher exact test (for small samples). Receiver operating characteristic curves were constructed to determine cut-off values. Identification of an optimal cut-off value was based on the maximum Youden's index \[[@b22-kjim-2018-169]\]. To determine whether MALDI-TOF MS--based microorganism identification served as an independent prognostic factor for 28-day mortality, logistic regression analyses were performed with the inclusion of variables with *p* \< 0.05 in univariate analyses. All statistical analyses were performed using the SPSS version 22.0 (IBM Co., Armonk, NY, USA) and MedCalc Statistical Software version 18.5 (MedCalc Software, Ostend, Belgium). Two-tailed p values \< 0.05 were considered to indicate statistical significance.

RESULTS
=======

Baseline characteristics
------------------------

In total, 1,283 patients in the ICU had positive blood cultures during the two study periods. After applying the eligibility criteria, 187 patients were enrolled in the study ([Fig. 1](#f1-kjim-2018-169){ref-type="fig"}). Blood for microorganism culture was collected 28.2 ± 117.3 days after admission to the ICU. Respiratory infections were the most common source of bacteremia (39.0%), and MRSA was the most commonly identified microorganism (39.6%). During the study period, the total mortality rate in the 28 days after venipuncture for microorganism culture was 38.0%. [Table 1](#t1-kjim-2018-169){ref-type="table"} shows the clinical characteristics of all patients, survivors, and non-survivors. Compared with survivors, non-survivors were more likely to require ventilator care, vasopressors, renal replacement therapy, and neuromuscular blocking agents on the day of blood collection for microorganism culture.

Comparison of the pre-intervention and intervention groups
----------------------------------------------------------

Of the 187 patients enrolled in the study, 97 were in the pre-intervention group and 90 were in the intervention group. The most common microorganisms in the pre-intervention and intervention groups were MRSA and CRAB, respectively ([Table 2](#t2-kjim-2018-169){ref-type="table"}). However, the two groups did not differ in terms of frequencies of infection with different microorganisms.

The intervention group had a significantly shorter average time from venipuncture to microorganism identification and antimicrobial susceptibility test results than the pre-intervention group (*p* = 0.038) ([Table 2](#t2-kjim-2018-169){ref-type="table"}, [Fig. 2](#f2-kjim-2018-169){ref-type="fig"}). However, when the groups were divided according to the causative microorganism, they did not differ in terms of this variable ([Table 2](#t2-kjim-2018-169){ref-type="table"}).

In total, 143 of the 187 patients (76.5%) received antibiotics for more than 3 days in the 3 months before blood culture. The two groups did not differ in terms of this variable (*p* = 0.685). [Table 3](#t3-kjim-2018-169){ref-type="table"} shows the antibiotics that were used for more than 3 days in the 3 months before blood culture. In both groups, glycopeptides and carbapenems were the most commonly used antibiotics. The frequency with which patients were given different types of antibiotics in the 3 months before blood culture did not differ between groups ([Table 3](#t3-kjim-2018-169){ref-type="table"}). Of the 187 study patients, 122 (65.2%) required consultation with an ID specialist ([Fig. 3](#f3-kjim-2018-169){ref-type="fig"}). The intervention group had more consultations with an ID specialist than the pre-intervention group (74.4% vs. 56.7%, *p* = 0.014).

The antibiotics used were adjusted in 52 patients (27.8%) based on microorganism identification and antimicrobial susceptibility test results. Of these, 26 were in the pre-intervention group and 26 were in the intervention group. The pre-intervention and intervention groups did not differ in terms of the frequency of antibiotic adjustment (*p* = 0.751). The most common adjustment in both groups was a change to treat CRAB (32.7%), followed by a change to treat ESBL-producing Gram-negative bacteria (21.2%). However, the two groups did not differ significantly in terms of average time from venipuncture to antibiotic adjustment ([Fig. 2](#f2-kjim-2018-169){ref-type="fig"}). Of the 135 patients who did not undergo adjustment of antibiotics, 70 (51.9%) had the same microorganisms in non-blood specimens that were taken before the blood culture ([Fig. 3](#f3-kjim-2018-169){ref-type="fig"}). No difference was noted in the frequency of this variable between groups (*p* = 0.490).

Effect of MALDI-TOF MS--based microorganism identification on clinical outcomes
-------------------------------------------------------------------------------

The two groups did not differ in terms of the mortality rate within 28 days of venipuncture (40.2% in the pre-intervention group and 35.6% in the intervention group, *p* = 0.549). In addition, the in-hospital mortality rate did not differ between groups (48.5% in the pre-intervention group and 46.7% in the intervention group, *p* = 0.807). To evaluate the prognostic utility of MALDI-TOF MS, we assessed the mortality rates of the 52 patients who underwent antibiotic adjustment. MALDI-TOF MS was not significantly associated with this mortality rate (47.1% vs. 52.9%, *p* \> 0.999).

A multivariate logistic regression analysis of data from the 52 patients who underwent antibiotic adjustment showed that diabetes and malignant disease were comorbidities independently associated with 28-day mortality. However, MALDI-TOF MS--based microorganism identification was not associated with 28-day mortality ([Table 4](#t4-kjim-2018-169){ref-type="table"}).

DISCUSSION
==========

This study is the first to examine the clinical efficacy of MALDI-TOF MS--based microorganism identification for patients with MDR bacteremia in ICUs in Korea. The use of MALDI-TOF MS for microorganism identification significantly reduced the time from venipuncture to microorganism identification and antimicrobial susceptibility test results, but did not significantly impact survival, in our cohort of patients with MDR bacteremia in the ICU.

Our finding that MALDI-TOF MS reduces the time from venipuncture to microorganism identification and antimicrobial susceptibility test results is consistent with the findings of several studies \[[@b12-kjim-2018-169]-[@b14-kjim-2018-169],[@b23-kjim-2018-169]-[@b25-kjim-2018-169]\]. However, one marked difference between previous studies and our findings is that both groups, particularly the intervention group, in our study had longer times from venipuncture to microorganism identification and antimicrobial susceptibility test results (92.3 and 82.5 hours in the pre-intervention and intervention groups, respectively) than did equivalent groups in previous studies (48.0 to 84.0 and 23.0 to 55.9 hours, respectively) \[[@b13-kjim-2018-169],[@b24-kjim-2018-169]\]. This difference may reflect our hospital's policy of performing microorganism identification tests once per day due to limited resources (e.g., excessive workload and lack of manpower). To improve the clinical usefulness of MALDI-TOF MS, universal protocols must be established.

Our study demonstrated that the use of MALDI-TOF MS to identify bacteremia-causing microorganisms in patients in the ICU was not associated with 28-day mortality. This finding may reflect the fact that most patients had received empirical broad-spectrum antibiotics before blood microorganism identification and antimicrobial susceptibility testing. Moreover, in 37% of the patients, the same microorganisms had been identified in non-blood specimens (e.g., sputum and urine) taken before the bacteremia arose. Thus, in approximately one-third of patients, the antibiotics administered had already been adjusted before bacteremia developed and blood was taken for culture. These factors may have limited the ability of our study to detect a significant effect of MALDI-TOF MS on mortality rates.

One of the most important findings of our study is that the time from blood culture to antibiotic adjustment did not differ between the pre-intervention and intervention groups, meaning that the advantage of rapid microorganism identification by MALDI-TOF MS did not result in rapid antibiotic adjustment. Although this result may be attributable to the small number of patients who underwent antibiotic adjustment in our study, our findings suggest that optimal interventions are needed not only for real-time notification to attending physicians regarding pathogen identification, but also for reinforcement of antimicrobial stewardship programs. Despite the severity of MDR bacteremia, only One of the most important findings of our study is that the time from blood culture to antibiotic adjustment did not differ between the pre-intervention and intervention groups, meaning that the advantage of rapid microorganism identification by MALDI-TOF MS did not result in rapid antibiotic adjustment. Although this result may be attributable to the small number of patients who underwent antibiotic adjustment in our study, our findings suggest that optimal interventions are needed not only for real-time notification to attending physicians regarding pathogen identification, but also for reinforcement of antimicrobial stewardship programs. Despite the severity of MDR bacteremia, only 65% of our patients had consultations with an ID specialist. Moreover, only 24% of these patients had changes to their antimicrobial treatment that were suggested by an ID specialist. These findings may be typical of the situation in Korea, where few antimicrobial stewardship programs have been established. This factor may be responsible for the recent increase in the consumption of empirical broad-spectrum antibiotics in Korea \[[@b26-kjim-2018-169]\]. Well-regulated antimicrobial stewardship is known to be essential for limiting multidrug resistance worldwide \[[@b27-kjim-2018-169],[@b28-kjim-2018-169]\]. Indeed, the treatment of patients with MDR bacteremia significantly improves when rapid diagnostics is coupled with antibiotic stewardship \[[@b11-kjim-2018-169]-[@b13-kjim-2018-169],[@b29-kjim-2018-169]\]. In addition, a study showed that the combination of MALDI-TOF MS and real-time antimicrobial stewardship could achieve optimal treatment outcomes as well as a faster time to optimal antimicrobial therapy compared with MALDI-TOF MS alone \[[@b30-kjim-2018-169]\]. Therefore, the development of a well-regulated national antibiotic stewardship program combined with rapid diagnostic tests (i.e., those based on MALDI-TOF MS) is necessary in our country. Antimicrobial stewardship programs should have a multidisciplinary approach, including an attending physician, ID physician(s), and ID pharmacist(s), as well as real-time notifications to the attending physician(s) regarding pathogen identification \[[@b12-kjim-2018-169],[@b30-kjim-2018-169]\].

Our study has several limitations. First, it had a non-randomized design and was retrospective in nature, which may have resulted in selection bias. Second, our before-after design may not have taken into account changes in the standard of care over the study period that may have improved mortality. However, no significant change in standard sepsis management occurred during the study period. Third, our data are from a single center, and thus the results may not be representative of the general situation in Korea. Finally, we had a small sample, which prevented us from assessing the prognostic utility of MALDI-TOF MS in patients with specific bacteria or sources of infection.

In conclusion, the present study showed that MALDI-TOF MS reduced the time from venipuncture to microorganism identification and antimicrobial susceptibility testing. However, it did not serve as a prognostic indicator in patients with MDR bacteremia. This result may reflect the limitations of this study. Prospective large-scale studies of the optimal use and prognostic utility of MALDI-TOF MS--based microorganism identification in Korean ICUs are warranted.

KEY MESSAGE
===========

1\. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) accelerated microorganism identification in patients with multidrug-resistant bacteremia in the intensive care unit.

2\. However, MALDI-TOF MS--based microorganism identification did not influence 28-day mortality.
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###### 

Demographic and clinical characteristics of all enrolled patients and the survivors and non-survivors for 28 days after blood was drawn

  Characteristic                                                               Total (n = 187)   Survivors^[a](#tfn1-kjim-2018-169){ref-type="table-fn"}^ (n = 116)   Non-survivors (n = 71)   *p* value
  ---------------------------------------------------------------------------- ----------------- -------------------------------------------------------------------- ------------------------ -----------
  Age, yr                                                                      61.0 ± 16.6       59.5 ± 15.8                                                          63.3 ± 17.6              0.130
  Male sex                                                                     106 (56.7)        70 (60.3)                                                            36 (50.7)                0.197
  Comorbidities                                                                                                                                                                                
   Diabetes mellitus                                                           53 (28.3)         35 (30.2)                                                            18 (25.4)                0.478
   Cardiovascular disease                                                      46 (24.6)         28 (24.1)                                                            18 (25.4)                0.852
   Hemato-oncological disease                                                  42 (22.5)         12 (10.3)                                                            30 (42.3)                \< 0.001
   Cerebrovascular disease                                                     33 (17.6)         24 (20.7)                                                            9 (12.7)                 0.163
   Neuromuscular disease                                                       20 (10.7)         12 (10.3)                                                            8 (11.3)                 0.843
   Chronic renal disease                                                       18 (9.6)          13 (11.2)                                                            5 (7.0)                  0.349
   Chronic liver disease                                                       15 (8.0)          10 (8.6)                                                             5 (7.0)                  0.700
   Chronic lung disease                                                        15 (8.0)          8 (6.9)                                                              7 (9.9)                  0.469
   Rheumatological disease                                                     8 (4.3)           4 (3.4)                                                              4 (5.6)                  0.481
   Biliary disease                                                             5 (2.7)           3 (2.6)                                                              2 (2.8)                  \> 0.999
   Gastrointestinal disease                                                    5 (2.7)           3 (2.6)                                                              2 (2.8)                  \> 0.999
  APACHE II score^[b](#tfn2-kjim-2018-169){ref-type="table-fn"}^               17.5 ± 6.7        15.7 ± 6.3                                                           20.4 ± 6.3               \< 0.001
  SOFA score^[b](#tfn2-kjim-2018-169){ref-type="table-fn"}^                    7.5 ± 4.1         6.0 ± 3.3                                                            9.8 ± 4.3                \< 0.001
  Requirement for vasopressor^[b](#tfn2-kjim-2018-169){ref-type="table-fn"}^   75 (40.1)         31 (26.7)                                                            44 (62.0)                \< 0.001
  Requirement for RRT^[b](#tfn2-kjim-2018-169){ref-type="table-fn"}^           38 (20.3)         15 (12.9)                                                            23 (32.4)                0.001
  Requirement for NMB^[b](#tfn2-kjim-2018-169){ref-type="table-fn"}^           27 (14.4)         11 (9.5)                                                             16 (22.5)                0.014
  Requirement for MV^[b](#tfn2-kjim-2018-169){ref-type="table-fn"}^            124 (66.3)        68 (58.6)                                                            56 (78.9)                0.004
  Duration of MV, day                                                          30.9 ± 55.4       34.0 ± 53.7                                                          27.1 ± 57.7              0.494
  Hospital LOS, day                                                            71.6 ± 77.6       92.2 ± 82.3                                                          37.4 ± 54.5              \< 0.001
  ICU LOS, day                                                                 35.3 ± 50.0       40.1 ± 48.5                                                          27.2 ± 51.7              0.087
  Infection source                                                                                                                                                                             
   Respiratory                                                                 73 (39.0)         46 (39.7)                                                            27 (38.0)                0.825
   Vascular catheter-related                                                   30 (16.0)         18 (15.5)                                                            12 (16.9)                0.802
   Musculoskeletal                                                             16 (8.6)          13 (11.2)                                                            3 (4.2)                  0.098
   Intraabdominal                                                              14 (7.5)          10 (8.6)                                                             4 (5.6)                  0.451
   Urinary                                                                     12 (6.4)          10 (8.6)                                                             2 (2.8)                  0.137
   Skin and soft tissue                                                        12 (6.4)          7 (6.0)                                                              5 (7.0)                  0.768
   Unidentified                                                                30 (16.0)         12 (10.3)                                                            18 (25.4)                0.007
  Microorganism identified                                                                                                                                                                     
   Methicillin-resistant *Staphylococcus aureus*                               74 (39.6)         59 (50.9)                                                            15 (21.1)                \< 0.001
   Carbapenem-resistant *Acinetobacter baumannii*                              54 (28.9)         29 (25.0)                                                            25 (35.2)                0.135
   ESBL(+) *Klebsiella pneumoniae*                                             22 (11.8)         15 (12.9)                                                            7 (9.9)                  0.527
   Vancomycin-resistant *Enterococcus faecium*                                 20 (10.7)         3 (2.6)                                                              17 (23.9)                \< 0.001
   ESBL(+) *Escherichia coli*                                                  11 (5.9)          7 (6.0)                                                              4 (5.6)                  \> 0.999
   Carbapenem-resistant *Pseudomonas aeruginosa*                               6 (3.2)           3 (2.6)                                                              3 (4.2)                  0.675

Values are presented as mean ± SD or number (%).

APACHE, Acute Physiology and Chronic Health Evaluation; SOFA, Sequential Organ Failure Assessment; RRT, renal replacement therapy; NMB, neuromuscular blockade; MV, mechanical ventilation; LOS, length of stay; ICU, intensive care unit; ESBL, extended-spectrum β-lactamase.

Survivors were defined as patients who survived for 28 days after blood was drawn.

Based on the clinical data that were recorded on the day on which blood was drawn.

###### 

Comparison of the pre-intervention and intervention groups in terms of microorganism-related variables

  Variable                                                                                           Pre-intervention group (n = 97)   Intervention group (n = 90)   *p* value
  -------------------------------------------------------------------------------------------------- --------------------------------- ----------------------------- -----------
  Identified microorganisms                                                                                                                                          
   Methicillin-resistant *Staphylococcus aureus*                                                     44 (45.5)                         30 (33.3)                     0.093
   Carbapenem-resistant *Acinetobacter baumannii*                                                    23 (23.7)                         31 (34.4)                     0.106
   ESBL(+) *Klebsiella pneumoniae*                                                                   13 (13.4)                         9 (10.0)                      0.471
   Vancomycin-resistant *Enterococcus faecium*                                                       7 (7.2)                           13 (14.4)                     0.110
   ESBL(+) *Escherichia coli*                                                                        6 (6.2)                           5 (5.6)                       0.855
   Carbapenem-resistant *Pseudomonas aeruginosa*                                                     4 (4.1)                           2 (2.2)                       0.684
  Time from venipuncture to microorganism identification and antibiotics susceptibility result, hr                                                                   
   All microorganisms                                                                                92.3 ± 40.4                       82.5 ± 21.6                   0.038
   Methicillin-resistant *Staphylococcus aureus*                                                     91.9 ± 33.9                       85.4 ± 20.9                   0.357
   Carbapenem-resistant *Acinetobacter baumannii*                                                    87.3 ± 54.5                       77.3 ± 16.4                   0.338
   ESBL(+) *Klebsiella pneumoniae*                                                                   77.6 ± 24.7                       75.7 ± 22.2                   0.854
   Vancomycin-resistant *Enterococcus faecium*                                                       108.0 ± 48.8                      96.7 ± 29.5                   0.522
   ESBL(+) *Escherichia coli*                                                                        113.1 ± 37.2                      77.6 ± 19.4                   0.088
   Carbapenem-resistant *Pseudomonas aeruginosa*                                                     115.5 ± 35.1                      70.3 ± 17.7                   0.174

Values are presented as number (%) or mean ± SD.

ESBL, extended-spectrum β-lactamase.

###### 

Comparison of the pre-intervention and intervention groups in terms of antibiotics that were used for more than 3 days in the 3 months before venipuncture for blood culture

  Antibiotic                         Pre-intervention group (n = 97)   Intervention group (n = 90)   *p* value
  ---------------------------------- --------------------------------- ----------------------------- -----------
  Glycopeptides                      49 (50.5)                         57 (63.3)                     0.077
  Carbapenems                        47 (48.5)                         41 (45.6)                     0.692
  Fluoroquinolones                   38 (39.2)                         43 (47.8)                     0.236
  Third-generation cephalosporins    41 (42.3)                         33 (36.7)                     0.434
  Anti-pseudomonal penicillins       25 (25.8)                         27 (30.0)                     0.519
  Fourth-generation cephalosporins   18 (18.6)                         27 (30.0)                     0.067
  Colistin                           9 (9.3)                           17 (18.9)                     0.058
  Aminoglycosides                    9 (9.3)                           12 (13.3)                     0.380
  Minocycline                        4 (4.1)                           10 (11.1)                     0.070
  Macrolide                          6 (6.2)                           1 (1.1)                       0.120
  Second-generation cephalosporins   4 (4.1)                           2 (2.2)                       0.684
  Linezolid                          3 (3.1)                           3 (3.3)                       \> 0.999
  Trimethoprim-sulfamethoxazole      3 (3.1)                           2 (2.2)                       \> 0.999
  Tigecycline                        2 (2.1)                           0                             0.498

Values are presented as number (%).

###### 

Factors that associated with 28-day mortality^[a](#tfn3-kjim-2018-169){ref-type="table-fn"},[b](#tfn4-kjim-2018-169){ref-type="table-fn"}^

  Factor                                                                Univariate   Multivariate                                    
  --------------------------------------------------------------------- ------------ --------------- ------- ------- --------------- -------
  APACHE II score ≥ 18^[c](#tfn5-kjim-2018-169){ref-type="table-fn"}^   3.556        1.006--12.562   0.049                           
  SOFA score ≥ 9^[c](#tfn5-kjim-2018-169){ref-type="table-fn"}^         2.182        0.598--7.961    0.237                           
  Diabetes as a comorbidity                                             4.296        1.176--15.702   0.027   5.608   1.306--24.081   0.020
  Malignant disease as a comorbidity                                    4.227        1.002--17.843   0.050   6.383   1.262--32.283   0.025
  Vancomycin-resistant *Enterococcus faecium* bacteremia                9.000        1.580--51.261   0.013                           
  Consultation with an infectious diseases specialist                   0.145        0.025--0.852    0.033                           
  Microorganism identification via MALDI-TOF MS                         1.191        0.373--3.801    0.768                           

OR, odds ratio; CI, confidence interval; APACHE, Acute Physiology and Chronic Health Evaluation; SOFA, Sequential Organ Failure Assessment; MALDI-TOF MS, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.

Defined as death within 28 days after venipuncture for blood culture.

In total, 52 patients (26 in the pre-intervention group and 26 in the intervention group) who underwent antibiotics adjustment were included in this analysis.

Based on the clinical data that were recorded on the day of venipuncture. Identification of an optimal cut-off value was based on the maximum Youden's index.
